Brain damage from adolescent THC exposure in female rats was reversed by boosting the body's own endocannabinoids
Depressive-like behavior and brain changes caused by adolescent THC exposure in female rats were rescued by treatment with a FAAH inhibitor in adulthood, restoring synaptic plasticity and neurogenesis.
Quick Facts
What This Study Found
Female rats exposed to THC during adolescence developed depressive-like behaviors and measurable brain changes in adulthood. Researchers tested whether boosting endocannabinoid levels by inhibiting the enzyme FAAH (which breaks down anandamide) could reverse these effects.
The FAAH inhibitor URB597 successfully rescued multiple brain changes caused by adolescent THC. In the prefrontal cortex, it restored deficits in endocannabinoid-mediated signaling and synaptic plasticity that had been disrupted by THC exposure. In the hippocampus, it recovered normal levels of neurogenesis (the birth of new neurons) in the dentate gyrus.
Critically, the rescue of depressive-like behavior required functional CB1 receptors, confirming that the therapeutic effect operated through the endocannabinoid system. This suggests that adolescent THC exposure creates lasting deficits in endocannabinoid tone that can be corrected by boosting endocannabinoid levels in adulthood.
Key Numbers
Adolescent THC caused: deficits in prefrontal endocannabinoid signaling, impaired synaptic plasticity, reduced hippocampal neurogenesis, depressive-like behavior. URB597 rescued: endocannabinoid signaling, synaptic plasticity, neurogenesis, depressive-like behavior. Rescue required CB1 receptor activity.
How They Did This
Female rats received THC during adolescence. In adulthood, they received the FAAH inhibitor URB597 or vehicle. Biochemical, morphofunctional, and electrophysiological studies assessed endocannabinoid signaling and synaptic plasticity in the prefrontal cortex and neurogenesis in the hippocampal dentate gyrus.
Why This Research Matters
This study demonstrates that brain changes from adolescent cannabis exposure are not necessarily permanent and can potentially be reversed by pharmacological intervention in adulthood. The specific mechanism, restoring endocannabinoid tone, provides a therapeutic target for addressing the mood and cognitive consequences of adolescent cannabis use.
The Bigger Picture
The concept that adolescent cannabis damage can be repaired by modulating the endocannabinoid system offers hope for the growing population of adults who used cannabis heavily during adolescence. Rather than viewing adolescent-onset effects as irreversible, this research opens a therapeutic avenue focused on endocannabinoid restoration.
What This Study Doesn't Tell Us
This is an animal study using female rats only, and results may not translate to humans. The THC exposure regimen may not reflect typical human adolescent use patterns. URB597 is a research tool, not a clinically available medication. The study assessed depressive-like behaviors, which are imperfect models of human depression. Long-term durability of the rescue was not assessed.
Questions This Raises
- ?Would FAAH inhibitors show the same benefits in male rats exposed to adolescent THC?
- ?Could FAAH inhibitors be developed for clinical use in humans with adolescent-onset cannabis-related mood disorders?
- ?Are the rescued brain changes maintained after stopping URB597 treatment?
Trust & Context
- Key Stat:
- FAAH inhibitor reversed brain damage and depressive behavior from adolescent THC
- Evidence Grade:
- This is a well-designed animal study with multiple outcome measures and mechanistic validation, providing moderate evidence for a potential therapeutic approach.
- Study Age:
- Published in 2018. FAAH inhibitor development for human use has had a complex history.
- Original Title:
- Adult Cellular Neuroadaptations Induced by Adolescent THC Exposure in Female Rats Are Rescued by Enhancing Anandamide Signaling.
- Published In:
- The international journal of neuropsychopharmacology, 21(11), 1014-1024 (2018)
- Authors:
- Cuccurazzu, Bruna, Zamberletti, Erica(6), Nazzaro, Cristiano, Prini, Pamela, Trusel, Massimo, Grilli, Mariagrazia, Parolaro, Daniela, Tonini, Raffaella, Rubino, Tiziana
- Database ID:
- RTHC-01634
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can the brain recover from teenage cannabis use?
In this study, brain changes caused by adolescent THC exposure in rats were reversed by boosting endocannabinoid levels in adulthood. Synaptic plasticity, neurogenesis, and depressive-like behavior all improved. Whether this translates to humans is not yet known.
How does the treatment work?
The FAAH inhibitor URB597 blocks the enzyme that breaks down anandamide, one of the brain's own endocannabinoids. This raises endocannabinoid levels, which in turn restores the normal signaling and brain plasticity that adolescent THC had disrupted.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-01634APA
Cuccurazzu, Bruna; Zamberletti, Erica; Nazzaro, Cristiano; Prini, Pamela; Trusel, Massimo; Grilli, Mariagrazia; Parolaro, Daniela; Tonini, Raffaella; Rubino, Tiziana. (2018). Adult Cellular Neuroadaptations Induced by Adolescent THC Exposure in Female Rats Are Rescued by Enhancing Anandamide Signaling.. The international journal of neuropsychopharmacology, 21(11), 1014-1024. https://doi.org/10.1093/ijnp/pyy057
MLA
Cuccurazzu, Bruna, et al. "Adult Cellular Neuroadaptations Induced by Adolescent THC Exposure in Female Rats Are Rescued by Enhancing Anandamide Signaling.." The international journal of neuropsychopharmacology, 2018. https://doi.org/10.1093/ijnp/pyy057
RethinkTHC
RethinkTHC Research Database. "Adult Cellular Neuroadaptations Induced by Adolescent THC Ex..." RTHC-01634. Retrieved from https://rethinkthc.com/research/cuccurazzu-2018-adult-cellular-neuroadaptations-induced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.